Fully human therapeutic monoclonal antibodies.

  title={Fully human therapeutic monoclonal antibodies.},
  author={Louis M. Weiner},
  journal={Journal of immunotherapy},
  volume={29 1},
Monoclonal antibody (mAb) therapy has been facilitated by a number of technologic advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but… CONTINUE READING